Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin M Bednar

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
JAMA Otolaryngology-- Head & Neck Surgery|May 22, 2015
The Safety and Efficacy of PF-04958242 in Age-Related Sensorineural Hearing Loss: A Randomized Clinical TrialMartin M Bednar, Nick DeMartinis, Anindita Banerjee, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 18, 2013
Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation studyIzuru Miyoshi, Yoko Fujimoto, Masahito Yamada, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB studyJaren W Landen, Niels Andreasen, Carol L Cronenberger, et al.
Clinical Neuropharmacology|January 22, 2013
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer diseaseAaron H Burstein, Qinying Zhao, Joel Ross, et al.
British Journal of Clinical Pharmacology|May 15, 2021
Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1AWei Yin, Dimitrios Arkilo, Polyna Khudyakov, et al.
Clinical Neuropharmacology|January 22, 2013
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation studyJaren W Landen, Qinying Zhao, Sharon Cohen, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 5, 2020
The pathway to secondary prevention of Alzheimer's diseaseEric McDade, Martin M Bednar, H Robert Brashear, et al.
Annals of Clinical and Translational Neurology|April 26, 2019
Immunotherapy with ponezumab for probable cerebral amyloid angiopathyClaire Leurent, James A Goodman, Yao Zhang, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacyJaren W Landen, Sharon Cohen, Clare B Billing, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable WorkgroupReisa A Sperling, Clifford R Jack, Sandra E Black, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
JAMA Otolaryngology-- Head & Neck Surgery|May 22, 2015
The Safety and Efficacy of PF-04958242 in Age-Related Sensorineural Hearing Loss: A Randomized Clinical TrialMartin M Bednar, Nick DeMartinis, Anindita Banerjee, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 18, 2013
Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation studyIzuru Miyoshi, Yoko Fujimoto, Masahito Yamada, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB studyJaren W Landen, Niels Andreasen, Carol L Cronenberger, et al.
Clinical Neuropharmacology|January 22, 2013
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer diseaseAaron H Burstein, Qinying Zhao, Joel Ross, et al.
British Journal of Clinical Pharmacology|May 15, 2021
Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1AWei Yin, Dimitrios Arkilo, Polyna Khudyakov, et al.
Clinical Neuropharmacology|January 22, 2013
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation studyJaren W Landen, Qinying Zhao, Sharon Cohen, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 5, 2020
The pathway to secondary prevention of Alzheimer's diseaseEric McDade, Martin M Bednar, H Robert Brashear, et al.
Annals of Clinical and Translational Neurology|April 26, 2019
Immunotherapy with ponezumab for probable cerebral amyloid angiopathyClaire Leurent, James A Goodman, Yao Zhang, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacyJaren W Landen, Sharon Cohen, Clare B Billing, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable WorkgroupReisa A Sperling, Clifford R Jack, Sandra E Black, et al.
Pageof 3